IMCRImmunocore Holdings plc

IMCR Stock Price, Valuation & Chart | Immunocore Holdings plc

Compare

$37.370+0.51 (+1.38%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology IMCR intrinsic value IMCR calculated fair value vs price

Overview Financials Dividends Ratios

IMCR Historical price chart

IMCR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.90B

PE Ratio-105.4

EPS-0.35

Trading Volume220.69K

Today's High/Low37.95/36.23

Dividend Yield0.00

52 Week High/Low40.72/27.55

Shares Outstanding50.83M

IMCR Financial Statement

IMCR Analyst ratings

IMCR Analysis & performance metrics

IMCR Company profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune…

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in…

IMCR Management team

Name

Position

John Trainer M.B.A.COO

SVice President & Chief Operating Officer

Tina St. Leger

Executive Vice President & Chief Human Resources Officer

John Goll III

SVice President, Finance & Chief Accounting Officer

Lily Margaret Hepworth

Senior Vice President, General Counsel & Company Secretary

Annelise Vuidepot Ph.D.CTO

Senior Vice President, Chief Technology Officer and Research & UK Site Lead

Bahija Jallal Ph.D.CEO

Chief Executive Officer & Executive Director

David Berman M.D., Ph.D.

Executive Vice President of Research & Development

Travis A. CoyCFO

Chief Financial Officer, Executive Vice President & Head of Corporate Development

Name

Position

John Trainer M.B.A.COO

SVice President & Chief Operating Officer

Tina St. Leger

Executive Vice President & Chief Human Resources Officer

John Goll III

SVice President, Finance & Chief Accounting Officer

Lily Margaret Hepworth

Senior Vice President, General Counsel & Company Secretary

Annelise Vuidepot Ph.D.CTO

Senior Vice President, Chief Technology Officer and Research & UK Site Lead

Bahija Jallal Ph.D.CEO

Chief Executive Officer & Executive Director

David Berman M.D., Ph.D.

Executive Vice President of Research & Development

Travis A. CoyCFO

Chief Financial Officer, Executive Vice President & Head of Corporate Development

Management Team

John Trainer M.B.A.COO

SVice President & Chief Operating Officer

Tina St. Leger

Executive Vice President & Chief Human Resources Officer

John Goll III

SVice President, Finance & Chief Accounting Officer

Lily Margaret Hepworth

Senior Vice President, General Counsel & Company Secretary

Annelise Vuidepot Ph.D.CTO

Senior Vice President, Chief Technology Officer and Research & UK Site Lead

Bahija Jallal Ph.D.CEO

Chief Executive Officer & Executive Director

David Berman M.D., Ph.D.

Executive Vice President of Research & Development

Travis A. CoyCFO

Chief Financial Officer, Executive Vice President & Head of Corporate Development

Management

John Trainer M.B.A.COO

SVice President & Chief Operating Officer

Tina St. Leger

Executive Vice President & Chief Human Resources Officer

John Goll III

SVice President, Finance & Chief Accounting Officer

Lily Margaret Hepworth

Senior Vice President, General Counsel & Company Secretary

Annelise Vuidepot Ph.D.CTO

Senior Vice President, Chief Technology Officer and Research & UK Site Lead

Bahija Jallal Ph.D.CEO

Chief Executive Officer & Executive Director

David Berman M.D., Ph.D.

Executive Vice President of Research & Development

Travis A. CoyCFO

Chief Financial Officer, Executive Vice President & Head of Corporate Development

Total 8 executives

IMCR Frequently asked questions

What is Immunocore Holdings plc (IMCR) Stock Price?

Current stock price of Immunocore Holdings plc (IMCR) stock is $37.370. The stock price is +1.38% higher in the session. The intraday range can be seen from this page. Volume of Immunocore Holdings plc (IMCR) stock is 220.69K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Immunocore Holdings plc (IMCR) stock price going up or down today?

The stock price of Immunocore Holdings plc (IMCR) can change with earnings, company news, and overall market sentiment. Immunocore Holdings plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Immunocore Holdings plc stock expensive at its current price?

Whether Immunocore Holdings plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IMCR on this page is -105.44. EPS on this page is -0.35. Compare those figures with peers and growth expectations before deciding if the current Immunocore Holdings plc price is justified.

How has the stock price of Immunocore Holdings plc (IMCR) performed historically?

Historical performance for Immunocore Holdings plc (IMCR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IMCR reacted to past earnings and market events.

Should I buy Immunocore Holdings plc (IMCR) stock, at this price?

Buying Immunocore Holdings plc (IMCR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.